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Edited by Jesus AvilaAbstract We report that glycogen synthase kinase (GSK)-3b is
phosphorylated at ser9 and inactivated in uterine epithelial cells
from E2-treated cyclin D1 null mutant mice. Simultaneous
administration of P4 together with E2 blocked this eﬀect. Phar-
macological inhibition of GSK-3b activity in mice treated with
P4E2 reversed the nuclear exclusion of cyclin D2 in the uterine
epithelial cells and this caused phosphorylation of Rb protein
and progression of cells towards S-phase. Our results indicate
that GSK-3b is a major target of E2 and P4 in regulation of cy-
clin D2 localization in the mouse uterine epithelium.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The actions of ovarian steroid hormones estradiol-17b (E2)
and progesterone (P4) in the regulation of cell cycle has been
analyzed in in vivo and in vitro systems [1–3]. In the normal
uterus, ovarian E2 causes the uterine epithelial cells to undergo
rounds of cell proliferation [4]. In contrast, P4 inhibits this E2
induced cell proliferation and induces cell diﬀerentiation [5].
The cellular dynamics in the uterus can be faithfully repro-
duced by administration of exogenous female sex hormones
to adult female ovariectomized mice in regimens that are sim-
ilar to their physiological secretion level [6].
The sequential action of cyclins with their cyclin dependent
kinase (Cdk) partners regulates orderly cell cycle progression
during the G1–S phase transition. These cyclin and CDK holo-
enzymes include the cyclin D-Cdk4 and -Cdk6 complexes act-
ing in G1 and the cyclin E- and cyclin A-CDK2 complex acting
at the G1–S transition. Both kinase complexes inactivate Rb
family of proteins by phosphorylation. The D-type cyclinsAbbreviations: GSK, glycogen synthase kinase; E2, estradiol-17b; P4,
progesterone; CDK, cyclin dependent kinase
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act early in G1 phase. Although their expression show some-
what over-lapping patterns and can compensate for each
other, biochemical assays and the diﬀerent D-type cyclin deﬁ-
cient mice reveal functional diﬀerences among them [7].
As an important gate-keeper in G1–S phase transition, the
activity of cyclin Ds is tightly controlled. In cultured cells, it
is generally accepted that extracellular growth signals includ-
ing E2, cause an elevation in cyclin D1 concentration that acts
to activate Cdk4/6 by forming complexes that also titer away
the cell cycle inhibitor p27kip1 from the cyclin E/Cdk2 com-
plexes. However, in contrast to these studies in tissue culture,
we found that in uterine epithelial cells in vivo, E2 only induces
the nuclear accumulation of cyclin D1, which can be prevented
by P4 pretreatment [3,8]. Our previous studies also demon-
strated that cyclin D2 can compensate for the loss of cyclin
D1 in estrogen-induced epithelial cell proliferation in the
mouse uterus and in these circumstances, cyclin D2 accumu-
lates in the nucleus and the cells proceed normally into DNA
synthesis [8]. Although our studies in the mouse uterine epithe-
lium revealed that E2 and P4 regulates GSK-3b activity to con-
trol cyclin D1 localization [9], it is unclear how the localization
of cyclin D2 is regulated in vivo.
GSK-3b is implicated in many fundamental processes
among species, including glycogen and glucose metabolism,
embryonic cell fate determination, tumorigenesis, and apopto-
sis [10], suggesting a pivotal role of GSK-3b in cellular regula-
tion. Studies in mice and cell lines suggest there is a negative
correlation between GSK-3b and cyclin D2. B-cell receptor
signaling causes an inhibitory phosphorylation of GSK-3b,
and promotes cell progression, that is cyclin D2 dependent
[11,12]. Furthermore, inhibition of GSK-3b by LiCl can stim-
ulate cerebellar granule cell proliferation [13]. Consistent with
this, genetic disruption of cyclin D2 in mice leads to decrease in
granule cell number in the cerebellum [14], indicating the
requirement of cyclin D2 in granule cell proliferation.
In this paper, we investigated the regulation of cyclin D2
localization in cyclin D1-deﬁcient uterine epithelial cells in re-
sponse to E2 and P4. Disruption of GSK-3b function resulted
in an inhibition of the response to P4 in mouse uterine epithe-
lial cells in cyclin D1 deﬁcient mouse. These data show that
GSK-3b is one of the major regulators of cyclin D2 in vivo
and further emphasize the importance of GSK-3b in E2 and
P4 mediated signaling.blished by Elsevier B.V. All rights reserved.
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2.1. Animal treatment
Cyclin D1/ (Cdnd1) mice were a kind gift from Pitor Sicinski
(Dana-Farber Cancer Institute, Boston, MA). The mice were ovariec-
tomized via a dorsal incision under tribromoethanol anesthesia. Mice
were primed with 100 ng of E2 (Sigma, St. Louis, MO) for 2 d before
the experiment. Six days later, groups of three to ﬁve mice were killed
at various time points groups as described [9]. All experiments reported
here were repeated at least two to three times.
2.2. Preparation of epithelial cell extracts
After hormone treatment, uteri were removed and an epithelial ex-
tract of greater that 95% purity was prepared as described [15].
2.3. Western blot and antibodies
Polyclonal antibodies for cdk2 (sc-163), cdk4 (sc-260), cdk6 (sc-177),
p27 (sc-528), cyclin A (sc-597), and cyclin E (sc-481) were obtained
from Santa Cruz Biotechnology, Inc. Monoclonal antibodies for
pRb (G3-245) were obtained from Pharmingen; cyclin D2 (DCS-3.1)
was obtained from Neomarkers; and that for PCNA was obtained
from Boehringer Mannheim. The anti-phospho-Rb(ser807/811) and
anti-phospho-b-catenin(Ser33/37/Thr41) antibodies were acquired
from Cell Signaling. Western blotting was performed as described be-
fore. Quantitative analysis of at least three samples was performed by
densitometry of linearly exposed ﬁlms and expressed relative to the
GAPDH control.
2.4. Immunohistochemistry
Transverse 5-lm paraﬃn sections of the uterus were immunostained
for PCNA, cyclin D2 was subjected to antigen retrieval by boiling the
samples in 0.01 M sodium citrate buﬀer (pH 6.0) for 10 min. They were
washed and exposed to biotin-conjugated secondary antibodies, fol-
lowed by incubation with avidin DH-biotinylated horseradish peroxi-
dase H complex. Sections were counterstained with hematoxylin.
2.5. Preparation of a nuclear fraction from uterine epithelium
Uterine epithelial cell lysates were prepared as described [8]. The ly-
sates were vortexed for 20 s followed by repeated passing through a 22-
gauge needle. Nuclei were collected by centrifugation at 800 · g for
10 min.Fig. 1. P4 inhibited E2-induced GSK-3b phosphorylation and activity in c
hormone treatment were separated by SDS–PAGE, transferred to membran
form of GSK-3b. b-Catenin, and Ser33/37/Thr41-phosphorylated form
dehydrogenase (GAPDH) was used as loading control. Relative values o
densitometric analysis (means ± S.E. of the means). *P value from Student’s3. Results
3.1. Phosphorylation and activity of GSK-3b is regulated by E2
and P4 in cyclin D1/ mouse uterine epithelium
To investigate whether the nuclear accumulation of cyclin
D2 induced by E2 in the cyclin D1/ mouse uterine epithe-
lium which is inhibited by pre-treatment with P4, is regulated
by GSK-3b, we ﬁrst asked whether GSK-3b is regulated by
the steroid hormones in this mouse genetic background.
Uterine epithelial cellular extracts from ovariectomized cyclin
D1/ mouse that had been treated with E2 or P4E2 for 5 h
were subjected to Western blot analysis. As shown in Fig. 1,
GSK-3b protein concentration did not change in response to
the diﬀerent hormone treatment. With the phosphor-speciﬁc
antibody against GSK-3b, only a low level of GSK-3b phos-
phorylation at ser9 could be detected in the control uterine epi-
thelial extract of mice without any hormone treatment. E2
treatment, however, induced a substantial level of ser9 phos-
phorylation, whereas pretreatment with P4 reduced the phos-
phorylation of GSK-3b back to the level observed in control
condition (Fig. 1).
b-catenin, a major substrate of GSK-3b, is phosphorylated
by this enzyme at Ser33/37/Thr41[16]. We used its phosphory-
lation status as an indicator for GSK-3b activity. Phos-b-Cate-
nin at Ser33/37/Thr41 was detectable in the epithelium of
control un-treated cyclin D1/ mice (Fig. 1). In contrast,
E2 almost completely abolished phosphorylation at these sites,
and this was reversed by pre-treatment with P4. However, the
total expression level of b-catenin remained constant. GSK-3b
activity is therefore reciprocally regulated by E2 and P4.
3.2. Inhibition of GSK-3b leads to cyclin D2 nuclear
accumulation
The phosphorylation pattern and activity of GSK-3b
strongly correlated with cyclin D2 localization in uterineyclin D1/ mouse uterine epithelial cell lysates harvested 5 h after
es and probed with antibodies against GSK3-b, Ser9-phosphorylated
of b-catenin as indicated. Detection of glyceraldehyde-3-phosphate
f pGSK-3b and pb-catenin are shown for three determinations by
t-test was tested (P < 0.0011).
Fig. 2. Cyclin D2 sub-cellular localization in the cyclin D1/ mouse uterine epithelium following diﬀerent treatments. (A) Expression level of
b-catenin, and Ser33/37/Thr41-phosphorylated form of b-catenin in the uterine epithelium following either P4E2 treatment alone or in combination
with LiCl for 7 h was analyzed by Western blotting using corresponding antibodies. (B) 1–6, Localization of cyclin D2 as determined by
immunohistochemistry with an anti-cyclin D2 antibody of cross section of uteri from cyclin D1/ mice treatment as indicated. The brown color
represents the positive staining and the columnar cells are the luminal epithelium. (C) Western blotting analysis of total cellular or nuclear fractions
of uterine epithelial cells from cyclin D1/ mice treated as indicated above and probed with antibodies against cyclin D2 or lamin A/C as the
loading control. Relative values are shown for three determinations by densitometric analysis (means ± S.E. of the means). *P value from Student’s
t-test was tested (P < 0.0007). (D) Localization of cyclin D2 as determined by immunohistochemistry with an anti-cyclin D2 antibody of cross section
of uteri from cyclin D1/ mice treatment as indicated. (E) Western blotting analysis of total cellular or nuclear fractions of uterine epithelial cells
from cyclin D1/ mice treated as indicated above and probed with antibodies against cyclin D2 or lamin A/C as the loading control.
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Fig. 3. Phosphorylation Status of pRb in cyclin D1/ uterine
epithelium. Extracts of the epithelial cells from mice treated as
indicated were subjected to Western blotting with anti-Rb and anti-
phospho-Rb (Ser807/811) antibodies. The hypo (pRb) and hyperphos-
phorylated (ppRb) bands are indicated by arrows. The histogram
indicates densitometric determination of the ratio of ppRb with pRb
for three independent determinations (means ± S.E. of the means).
*P value from Student’s t-test was tested (P < 0.003).
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described before [9]. This result suggests that the female sex
steroid hormones may exert their function through GSK-3b
to regulate cyclin D2 sub-cellular localization in cyclin D1/
mouse uterine epithelium. To test this possibility, we used the
chemical inhibitor of GSK-3b, LiCl, to explore the role of
GSK-3b. 50 ll of LiCl in a plutonic gel at the concentration
of 20 mM was injected into the uterine lumen of mice 2 h be-
fore E2 or P4E2 treatment. As assessed by immunoblotting of
uterine epithelial cell lysates from cyclin D1/ mice 7 h after
the P4E2 treatment for phosphorylated form of b-catenin at
Ser33/37/Thr41, essentially all of GSK-3b activity was inhib-
ited by LiCl (Fig. 2A).
We next examined the subcellular localization of cyclin D2
in response to LiCl treatment by immunostaining. In control
mice without any treatment, cyclin D2 in cyclin D1 null mice
was predominantly in the cytoplasm (Fig. 2B1). However, LiCl
treatment alone already induced nuclear localization of cyclin
D2 in 50% of uterine epithelium cells (Fig. 2B2). Seven hours
after E2 stimulation, most of the uterine epithelial cell nuclei
were strongly stained by the anti-cyclin D2 antibody
(Fig. 2B3). LiCl did not further enhance cyclin D2 accumula-
tion in E2 treated cyclin D1 null uteri (Fig. 2B4). In contrast,
although administration of P4 and E2 coincidently inhibited
nuclear localization of cyclin D2, blocking GSK-3b by LiCl re-
versed the localization of cyclin D2 back into the nucleus
(Fig. 2B5 and B7). To assure the nuclear accumulation of cy-
clin D2 by LiCl was not due to the side eﬀect of the increased
intra-luminal pressure, we also injected PBS to the P4E2 trea-
ted cyclin D1/ mice. As expected, this treatment did not
change the cytoplasmic localization of cyclin D2 (Fig. 2B6).
The nuclear accumulation of cyclin D2 in the epithelium of cy-
clin D1 null mice with diﬀerent treatment was conﬁrmed by
Western blotting of a nuclear fraction from uterine epithelial
cells against cyclin D2 (Fig. 2C, upper panel). However, in
all of the cyclin D1 null mice under diﬀerent treatments, the to-
tal cyclin D2 cellular concentration was similar (Fig. 2C). To
further conﬁrm the cyclin D2 localization after disruption of
GSK-3b activity, we used TDZD-8 from Merck [17], another
speciﬁc inhibitor against GSK-3b at the concentration of
10 uM, which demonstrated a similar eﬀect to LiCl (Fig. 2D
and E). These data strongly support the hypothesis that
GSK-3b mediates E2 and P4E2 regulated cyclin D2 subcellular
localization in the uterine epithelium of mice.
3.3. Cyclin D2 nuclear localization is suﬃcient for Rb
phosphorylation in the uterine epithelium of cyclin D1 null
mice
To address the consequence of LiCl triggered cyclin D2 nu-
clear accumulation in the P4E2-treated cyclin D1 null mice, we
tested whether Rb protein phosphorylation status was chan-
ged. Cellular extracts from cyclin D1 null uterine epithelium
isolated from mice following the diﬀerent treatments for 7 h
were subjected to analysis by Western blotting with antibody
against Rb protein. The slower migrating phosphorylated
form of Rb was distinct in the E2 treated sample. In the
P4E2 treated sample, only the faster migrating hypophosph-
orylated form of Rb. However, inactivation of GSK-3b by
LiCl signiﬁcantly elevated the amount of the hyperphospho-
rylated form of Rb protein to a level comparable that detected
in the uterine epithelial cells of cyclin D1 null mice treated
with E2 (Fig. 3). To further conﬁrm that cyclin D2/CDK4contributed this Rb phosphorylation, we used a phospo-spe-
ciﬁc antibody, which speciﬁcally recognized Rb proteins phos-
phorylated at Ser807/811, the sites whose phosphorylation is
catalyzed by CDK4/6 kinases [18]. Essentially, no phosphory-
lation of Rb at Ser807/811 could be detected in uterine epithe-
lium of cyclin D1 null mice treated with P4E2, while intra-
luminal administration of LiCl substantially increased this
phosphorylated form of Rb. These data suggest that by inhib-
iting GSK-3b function, cyclin D2 is relocalized to the nucleus,
therefore can access and phosphorylate its substrate, Rb pro-
tein.3.4. Inhibition of GSK-3b counteracts progesterone inhibition of
cell cycle progression in cyclin D1/ mice
E2 treatment of adult ovariecotmized mice results in cell pro-
liferation in the luminal epithelium, which peaks 15 h after
treatment [6]. P4 completely suppresses this E2 induced prolif-
eration as well as the basal epithelial cell growth [5]. Rb phos-
phorylation by LiCl in P4E2 treated cyclin D1/ mouse
suggests this would drive cell progression from G1 into S
phase. Therefore, we used proliferating cell nuclear antigen
(PCNA) as an index of cell progression. In the untreated mice,
there were a small number of PCNA positive cells in luminal
epithelium (Fig. 4A). Addition of LiCl into the uterine lumen
of the control untreated cyclin D1/ mice induced 50% of
epithelial cells to become PCNA positive. Fifteen hours after
E2 treatment, the majority of the luminal epithelial cells were
PCNA positive (Fig. 4A). P4 pretreatment completely abol-
ished the E2-induced as well as basal level of nuclear PCNA
in cyclin D1 null uterine epithelium, but it stimulated stromal
cell nuclear PCNA accumulation. Inhibition of GSK-3b activ-
ity in P4E2 treated mice induced cells to be PCNA positive in
both epithelium and stroma (Fig. 4A). GSK-3b inhibitor,
TDZD-8, demonstrated similar eﬀect to LiCl (Fig. 4B).
Fig. 4. Uterine PCNA nuclear accumulation in response to the various hormones and LiCl treatments (A) and (B), Immunohistochemistry with anti-
PCNA antibody followed by hematoxylin staining of transverse sections of uteri isolated from cyclin D1/ after the treatments as indicated. Brown
color represents the positive signal.
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progression in the GSK-3b inhibited cyclin D1 null uterine
epithelium treated with P4E2
To test if the cell cycle progression in GSK-3b inhibited cy-
clin D1 null mice treated with P4E2 was attributed to alter-
nated expression of other cyclins, CDKs or CKIs in G1/S
transition, we analyzed the uterine epithelial cellular concen-
tration of the cell cycle proteins. CDK2 and CDK4 were ex-
pressed at a constant level regardless of the treatment of
mice with steroid hormones or LiCl (Fig. 5A and B). E2 injec-
tion had little eﬀect on the cyclin E level. However, simulta-
neously administration of P4 with E2 decreased cyclin E
expression to about 50%. Inhibition of GSK-3b in P4E2 treated
cyclin D1 null mice did not restore the cyclin E level. Cyclin A
expression was induced by E2 in the cyclin D1/ uterine epi-
thelial cells. P4 injection inhibited this E2induction, which can-
not be restored by administration of LiCl to the uterine lumen.
Among the diﬀerent CKIs, we can only detect p27, whoseexpression levels did not change in response to steroid hor-
mones or the treatments of combinations of these hormones
with LiCl. Similarly, Western blotting of nuclear extract of
uterine epithelial cells from the cyclin D1 null mice 6 h after
treatment, revealed that LiCl injection to the animals treated
with P4E2 did not signiﬁcantly change the expression patterns
of the other cell cycle proteins (Fig. 5C). Therefore, the reason
why inhibition of GSK-3b function can counteract the P4 neg-
ative eﬀect on cell cycle progression in the cyclin D1 null uter-
ine epithelial cells is mainly due to the restoration of cyclin D2
nuclear accumulation.4. Discussion
In some breast cancer cell lines, E2 stimulate cyclin D1
expression, while P4 inhibit this event [19]. A recent publica-
tion reveals that GSK-3b mediates in the PTEN regulation
Fig. 5. Expression patterns of diﬀerent cell cycle proteins in cyclin D1/ mouse after diﬀerent treatments. (A) Uterine epithelial cell lysates from
cyclin D1/mice treated with various hormone and LiCl regimens as indicated, were harvested at 0, 3 and 9 h after treatment. These were subjected
to Western blot analysis with antibodies against cyclin A, cyclin E, CDK2, CDK4 and p27kip1. GAPDH was used as loading control in this assay. (B)
Densitometric analysis of the expression of CDK4, CDK2, cyclin E, p27 at diﬀerent time points after the hormonal treatments as indicated. Data
shown are the means ± S.D. of three experiments. (C) Western blotting analysis of nuclear fractions of uterine epithelial cells from cyclin D1/mice
treated as indicated above and probed with antibodies against c cyclin A, cyclin E, CDK2, CDK4 and p27kip1. GAPDH was used as loading control
in this assay, lamin A/C was used as loading control.
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[20]. However, in uterine epithelial cells in ovariectomized cy-
clin D1 null mice, GSK-3b activity only aﬀects the cellular
localization of cyclin D2 without changing its expression in re-
sponse to diﬀerent hormone treatment. Although increased
levels of cyclin D occur in diﬀerent cancer types, many studies
suggest these may not be the only reason for the transforming
ability of cyclin Ds. Indeed the importance of nuclear retention
of cyclin D1 has been shown in that the mutant non-phospho-
rylatible form of cyclin D1 that is refractory to nuclear export
is highly potent in transforming NIH3T3 cells [21]. In addition,
the mechanisms of stimulation of cell proliferation without
changing the expression level of cyclin D1 by E2 in this
in vivo uterine system has been investigated and shown to
act via GSK-3b [9]. Our ﬁndings further support the previous
data showing regulation of the subcellular localization of cy-
clin Ds by steroid hormones and suggest that this may be a
key event in the malignant transition to hormone dependent
tumors.
Interestingly, we found that the phosphorylation of b-cate-
nin is inhibited in E2 treated mice and reversed by P4E2 and
this is enacted by GSK-3b. In many systems the nuclear local-
ization of b-catenin is regulated by the Wnt pathway acting
through GSK-3b. Wnt signaling has been shown to be impor-
tant in steroid hormone regulated uterine growth [22]. How-
ever, in our previous studies we have shown that the sex
steroid hormone regulation of GSK-3b activity is exclusively
through a PI-3kinase/AKT pathway [9] suggesting that this
b-catenin phosphorylation is regulated by this route and not
the Wnt one. The relationship between these two pathways re-mains to be explored but is likely to be important in the con-
trol of uterine cell proliferation.
Compensatory mechanisms for the loss of one protein in the
cell cycle ﬁeld has not only been demonstrated within the same
family member proteins, but also among the diﬀerent cyclins or
CDKs [23]. However, LiCl injection into cyclin D1 null mice
did not signiﬁcantly change the expression patterns of diﬀerent
G1–S cell cycle proteins. Therefore, the reason why inhibition
of GSK-3b function can counteract the P4 negative eﬀect on cell
cycle in cyclin D1 null uterine epithelial cells is mainly due to
the restoration of cyclin D2 nuclear accumulation. These data
underlines the importance of cyclin D proteins in the regulation
of the whole cell cycle machinery in response to hormones
in vivo. In this uterine epithelial system, P4counteracts E2 by
inhibiting phosphorylation of GSK-3b, which consequently
inactivates cyclin D and stops cell cycle progression.
In summary, we show the mechanism that is responsible for
cyclin D2 nuclear accumulation in an in vivo physiologically
relevant system. These studies have further veriﬁed the impor-
tance of GSK-3b in the regulation of cell cycle progression.
Studies form the Roberts group have also reported that
GSK-3b kinase can regulate cell proliferation through CDK2
by controlling cyclin E degradation [24]. Therefore, these data
suggest that targeting GSK-3b pathway might be a good strat-
egy for cancer therapy.Acknowledgements: We especially thank Dr. Pitor Sicinski for gener-
ously providing the cyclin D1 mutant mice. This work was supported
by Chinese NSFC Grant 30600316 (to B.C.) and NIH RO1CA 89617
(to J.W.P).
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